(Q46488387)

22 December 2017

title

HIV and TB coinfection: using adjusted doses of lopinavir/ritonavir with rifampin (English)

1 reference

22 December 2017

1 reference

1 reference

1 reference

1

1 reference

22 December 2017

Esteban Ribera

series ordinal

2

1 reference

22 December 2017

publication date

1 December 2011

1 reference

22 December 2017

Expert Review of Anti-infective Therapy

published in

1 reference

22 December 2017

volume

9

1 reference

22 December 2017

issue

12

1 reference

22 December 2017

page(s)

1115-1118

1 reference

22 December 2017

Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.143

Pharmacokinetic interactions with rifampicin : clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.143

Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.143

High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.143

Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.143

Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.143

Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.143

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.143

Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.143

Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.143

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.143

Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.143

21 January 2018

Identifiers

DOI

10.1586/ERI.11.143

1 reference

22 December 2017

1 reference

22 December 2017